1 / 108

Doc, I Have This Drip ….

Doc, I Have This Drip …. Sexually Transmitted Diseases and HIV. Ronald D. Wilcox MD FAAP Project Director/Principal Investigator, Delta AIDS Education & Training Center Louisiana State University Health Sciences Center Depts. of Internal Medicine and Pediatrics Section of Infectious Diseases.

mort
Download Presentation

Doc, I Have This Drip ….

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Doc, I Have This Drip ….

  2. Sexually Transmitted Diseases and HIV Ronald D. Wilcox MD FAAP Project Director/Principal Investigator, Delta AIDS Education & Training Center Louisiana State University Health Sciences Center Depts. of Internal Medicine and Pediatrics Section of Infectious Diseases

  3. www.deltaaetc.org 504-903-0788 LPS Coordinator: Dana Gray

  4. ARS • This presentation will be using an audience response system to better involve the audience and help us determine your learning needs.

  5. Disclaimers • The presenter does not have any financial interests or affiliations that will influence the presentation • The presenter does not have any personal experience with these diseases so please do not ask • The presentation has a number of very graphic slides - You Have Been Warned!

  6. Question • Please describe your profession • 1. Infectious disease or STD specialist • 2. Primary care physician or Nurse Practitioner • 3. Nurse or Health Educator • 4. Case Manager / Social Worker / Other • 5. Person who was wandering by and came in to feel like they are a part of a crowd

  7. Question • How familiar are you with the CDC STD Guidelines from May, 2006? • 1. I have read them thoroughly • 2. I have looked over the charts and read some of the text • 3. I am somewhat familiar with them • 4. I know they are out there • 5. What are STDs and who is the CDC?

  8. Genital Ulcer Diseases • Initial work-up • Serologic testing for syphilis • Diagnostic evaluation for herpes simplex – culture or antigen testing • Depending on area, culture for H. ducreyi

  9. Question • What is the most common cause of genital ulcer disease in the United States? • 1. Treponema pallidum • 2. Herpes simplex virus – 1 • 3. Herpes simplex virus – 2 • 4. Haemophilus ducreyi • 5. Chlamydia sp.

  10. Herpes Simplex • Two serotypes: HSV-1 and HSV-2 • HSV-1 cause of up to 30% of primary herpes genitalis • Most common cause of genital ulcers in the USA • Most HSV-2 infected patients are unaware of status • Diagnosis: • clinical diagnosis should be confirmed by laboratory testing, either DFA or viral culture • PCR usually reserved for use in diagnosis of CNS infections • Tzanck preps insensitive and non-specific • Type-specific antibodies form within weeks

  11. Herpes Simplex – Primary Infection

  12. 2006 CDC STD Treatment GuidelinesPrimary Genital Herpes • Recommended Regimens (7-10 day duration): • Acyclovir 400 mg po tid OR 200 mg po 5x/day OR • Famciclovir 250 mg po tid OR • Valacyclovir 1 gm po bid

  13. Recurrent Herpes Simplex

  14. Herpes Simplex

  15. Herpetic Whitlow

  16. 2006 CDC STD Treatment Guidelines Recurrent Genital Herpes • Recommended Regimens: • Acyclovir 400 mg po tid OR 800 mg po bid x 5 days OR 800 mg po tid x 3 days OR • Famciclovir 125 mg po bid x 5 days OR 1000 mg po daily x 1 day OR • Valacyclovir 500 mg po bid x 3 days OR 1 gm po daily x 5 days

  17. 2006 CDC STD Treatment Guidelines Suppression of Genital Herpes • Recommended Regimens: • Acyclovir 400 mg po bid OR • Famciclovir 250 mg po bid OR • Valacyclovir 500 - 1000 mg po daily

  18. Herpes simplex • Higher doses of acyclovir may be required for oral HSV or HSV proctitis, ie 400 mg po five times daily • Suppressive dosing is used when recurrences occur > 6 episodes per year • Severe disease may require IV therapy at 5-10 mg/kg q8 (based on ideal body weight) for 2-7 days

  19. Herpes simplex • Counseling • Two main goals: • Help pts cope with the infection • Prevent sexual and perinatal passage • Important to stress that transmission still can occur even when asymptomatic due to shedding – more frequent in HSV-2 and in the first 12 months after infection • Latex condoms may decrease transmission • Risk for neonatal HSV should be explained to all patients, including men. Women who do not have HSV-2 should avoid sex with men with HSV in the third trimester

  20. Effect of HSV by HIV • Lesions may be prolonged or more severe • May have atypical appearance • Acyclovir-resistance is more common in HIV-infected persons and should be tested for if no response to therapy – also resistant to valacyclovir and possibly famciclovir • Use valacyclovir in those with CD4 < 200 very cautiously

  21. Question • Should all HIV+ patients be placed on acyclovir if they have a history of HSV infection? • 1. Yes, they all should • 2. Yes, if they have at least 2 episodes per year • 3. Yes, if they have at least 6 episodes per year • 4. No, they only need treatment when they have an outbreak

  22. Effect of HSV on HIV • Increased viral load with each outbreak • Resetting the HIV viral load baseline higher after the outbreak heals

  23. 2006 CDC STD Treatment Guidelines Episodic Genital Herpes in Persons with HIV Infection • Recommended Regimens: • Acyclovir 400 mg po tid x 5-10 days OR • Famciclovir 500 mg po bid x 5-10 days OR • Valacyclovir 1 gm po bid x 5-10 days

  24. 2006 CDC STD Treatment Guidelines Suppression of Genital Herpes in HIV-Infected Persons • Recommended Regimens: • Acyclovir 400-800 mg po bid - tid OR • Famciclovir 500 mg po bid OR • Valacyclovir 500 mg po bid

  25. Herpes simplex • In pregnancy: • 30-50% passage to infant in mothers who get primary infection near time of delivery; < 1% passage for asymptomatic mothers or those who get infection during first trimester • Delivery by c-section if mother has visible lesions reduces risk of transmission

  26. Neonatal Herpes • Localized: • Skin, Eyes, Mouth • CNS infection • Disseminated • Tx: Acyclovir 20 mg/kg/dose q8 for 14-21 days

  27. Question • Which bacterial organism is associated with painful genital ulcerations and tender regional LAD? 1.Staphylococcus aureus 2. Haemophilus ducreyi 3. Treponema pallidum 4. Calymmatobacterium granulomatis

  28. Chancroid • Causative organism: Haemophilus ducreyi • In US occurs in discrete outbreaks • Diagnosis is usually clinical • One or more painful genital ulcers • Clinical presentation, appearance, and possible presence of regional tender lymphadenopathy • No evidence of T. pallidum infection by serology or dark-field microscopy • Test for HSV from the ulcer is negative • 10% are co-infected with T. pallidum or HSV

  29. Chancroid

  30. Chancroid

  31. Chancroid Lymphadenopathy

  32. 2006 CDC STD Treatment GuidelinesChancroid • Recommended Regimens • Azithromycin 1 gm orally in a single dose OR • Ceftriaxone 250 mg IM in a single dose OR • Ciprofloxacin 500 mg po bid x 3 days OR • Erythromycin base 500 mg po tid x 7 days

  33. Chancroid • Patients who are HIV + or uncircumcised do not respond to treatment as well as usual or may require longer courses of antibiotics • Ulcers should resolve usually within 7 days but may take over 2 weeks for large ulcers or for uncircumcised men • Sexual partners need examination & treatment • Some experts recommend erythromycin if HIV+

  34. Granuloma inguinale(Donovanosis) • Causative agent: intracellular Calymmatobacterium granulomatis • Painless, progressive ulcerative lesions without suppurative regional lymphadenopathy • Ulcers highly vascular (“beefy red”) and bleed easily • Diagnosis by biopsy • Tx: recommended doxycycline or tmp/smx bid for at least three weeks

  35. Lymphogranuloma venereum • Causative agent: Chlamydia trachomatis serovars L1, L2, or L3 • Most common presentation tender inguinal/femoral LAD commonly unilateral • May cause proctocolitis or inflame perirectal or perianal lymphatic tissue • Diagnosis: clinical suspicion, epidemiologic information, and exclusion of other etiologies along with serology • Tx: Recommended: Doxycycline 100 mg po bid x 21 days (Alternative erythromycin base 500 mg po QID x 21 days) • No change in therapy if HIV+

  36. Question • Which of the following is/are non-treponemal screening tests for syphilis? • 1. VDRL • 2. RPR (rapid plasma reagin) • 3. FTA-ABS • 4. 1 & 2 • 5. All of the above

  37. Syphilis • Causative organism: Treponema pallidum • Diagnostic testing: • Darkfield examinations or Direct flourescent antibodies of tissue • Nontreponemal tests – quantitative • VDRL • RPR (rapid plasma reagin) • Treponemal test • FTA-ABS • TP-PA (particle agglutination)

  38. Primary Syphilis Incubation period 10-90 days (mean 3 weeks) Chancre: Painless, indurated, with sharp, raised border Non-treponemal tests + in only 50%

  39. Secondary Syphilis 3-6 weeks after appearance of the chancre Generalized bilaterally symmetrical maculopapular rash, involving palms & soles Patchy alopecia common Generalized LAD in 75% (esp epitrochlear) Condyloma lata Dry rash minimally contagious, wet areas highly contagious

  40. Condyloma lata

  41. 2006 CDC STD Treatment GuidelinesSyphilis – Primary & Secondary • Recommended Regimen: • Benzathine Penicillin G (Bicillin L-A) 50,000 units/kg IM in a single dose, up to the adult dose of 2.4 million units • 15% failure rate

  42. Latent Syphilis • Clinically silent stages: • Early – between primary & secondary • Late or unknown duration – after secondary • Diagnosed by serology • Need evaluation for presence of aortitis, gumma, iritis, and uveitis

  43. 2006 CDC STD Treatment GuidelinesLatent Syphilis • Recommended Regimens: • Early Latent • Benzathine Penicillin G 50,000 units/kg up to 2.4 million units in a single dose • Late Latent • Benzathine Penicillin G 50,000 units/kg up to 2.4 million units weekly for three doses

  44. Tertiary Syphilis Gummas – destructive lesions of skin or bones Aortic anheurysms Aortic Insufficiency Non-treponemal tests 70% sens

  45. 2006 CDC STD Treatment GuidelinesTertiary Syphilis • Recommended Regimen: • Benzathine Penicillin G (Bicillin L-A) 2.4 million units IM weekly for three doses

  46. 2006 CDC STD Treatment Guidelines Syphilis – Special Circumstances • Penicillin Allergy • Primary or Secondary • Doxycycline 100 mg po bid x 14 days OR • Tetracycline 500 mg po qid x 14 days OR • Desensitization to Penicillin if pregnant • Alternatives: Ceftriaxone 1 gm daily x 8-10 days OR Azithromycin 2 gms po x 1 * • Latent and Tertiary • Same as above but for 28 days

  47. Neurosyphilis • Lymphocytic meningitis – manifestation of primary or secondary syphilis or later as meningovascular syphilis • CVA in a young patient • Dementia secondary to General Paresis • Tabes dorsalis – stabbing pains due to posterior column disease • CSF: + VDRL (low sens) or elevated WBC or elevated protein • Some experts recommend FTA-ABS for CSF – has high sensitivity but low specificity

  48. 2006 CDC STD Treatment Guidelines Neurosyphilis • Recommended Regimen: • Aqueous Crystalline Penicillin G 3-4 million units every 4 hours (total 18-24 million units/day) or by continuous infusion • Alternative Regimen: • Procaine Penicillin 2.4 million units IM daily PLUSProbenecid 500 mg po qid x 10-14 days • Possibly: Ceftriaxone 2 gm daily x 10-14 days

  49. Early Congenital Syphilis • Osteochondritis (55%) • Snuffles • Rash (40%) • Anemia (30%) • Hepatosplenomegaly (20%) • Jaundice (20%) • Neurologic Signs (20%) • Pseudoparalysis of an extremity • Lymphadenopathy (5%) • Mucous patches (5%)

More Related